{"id":16948,"date":"2020-04-27T17:14:32","date_gmt":"2020-04-27T15:14:32","guid":{"rendered":"https:\/\/www.gsk.de\/?p=16948"},"modified":"2020-04-27T17:14:33","modified_gmt":"2020-04-27T15:14:33","slug":"salebility-bei-wachstumsunternehmen","status":"publish","type":"post","link":"https:\/\/gsk.de\/de\/salebility-bei-wachstumsunternehmen\/","title":{"rendered":"Salebility bei Wachstumsunternehmen"},"content":{"rendered":"\n<p>Ein Wachstumsunternehmen bis zu einer Exit-M\u00f6glichkeit zu f\u00fchren ist ein gro\u00dfer Erfolg. Eine weitere Herausforderung besteht darin, den Exit auch Realit\u00e4t werden zu lassen und m\u00f6glichst reibungslos abzuwickeln. Welche Regeln dabei zu beachten sind, erkl\u00e4rt Dr. Thomas Derlin, Partner bei GSK Stockmann, im Venture Capital Magazin, Ausgabe 02\/2020.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ein Wachstumsunternehmen bis zu einer Exit-M\u00f6glichkeit zu f\u00fchren ist ein gro\u00dfer Erfolg. Eine weitere Herausforderung besteht darin, den Exit auch Realit\u00e4t werden zu lassen und m\u00f6glichst reibungslos abzuwickeln. Welche Regeln dabei zu beachten sind, erkl\u00e4rt Dr. Thomas Derlin, Partner bei GSK Stockmann, im Venture Capital Magazin, Ausgabe 02\/2020.<\/p>\n","protected":false},"author":32,"featured_media":8085,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[282],"tags":[],"ausgabe":[669],"verknuepfung":[725,737,742],"class_list":["post-16948","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pressespiegel","ausgabe-gsk","verknuepfung-gesellschaftsrecht","verknuepfung-ma","verknuepfung-private-equity-venture-capital"],"acf":{"ansprechpartner":[{"anwalt":804}],"postdownloads":[{"download":"https:\/\/gsk.de\/wp-content\/uploads\/2020\/04\/2020-02_Venture-Capital_Die-Sicherstellung-der-Salebility-bei-Wachstumsunternehmen_Derlin.pdf","anzeigetitel":"Herunterladen"}]},"info":{"date":"27.04.2020","author":"GSK Sysop","categories_names":["Pressespiegel"],"category":"Pressespiegel"},"wpml_main_post_id":16948,"featured_img_src":"https:\/\/gsk.de\/wp-content\/uploads\/2019\/08\/GSK_Berlin_Thomas_Derlin_001.png","_links":{"self":[{"href":"https:\/\/gsk.de\/de\/wp-json\/wp\/v2\/posts\/16948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gsk.de\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/gsk.de\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/gsk.de\/de\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/gsk.de\/de\/wp-json\/wp\/v2\/comments?post=16948"}],"version-history":[{"count":0,"href":"https:\/\/gsk.de\/de\/wp-json\/wp\/v2\/posts\/16948\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/gsk.de\/de\/wp-json\/wp\/v2\/media\/8085"}],"wp:attachment":[{"href":"https:\/\/gsk.de\/de\/wp-json\/wp\/v2\/media?parent=16948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/gsk.de\/de\/wp-json\/wp\/v2\/categories?post=16948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/gsk.de\/de\/wp-json\/wp\/v2\/tags?post=16948"},{"taxonomy":"ausgabe","embeddable":true,"href":"https:\/\/gsk.de\/de\/wp-json\/wp\/v2\/ausgabe?post=16948"},{"taxonomy":"verknuepfung","embeddable":true,"href":"https:\/\/gsk.de\/de\/wp-json\/wp\/v2\/verknuepfung?post=16948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}